Publications

Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort.

• Author

  Layton D Shakir SAW. Coughtrie AL Behr ER Marshall V Camm AJ

  Layton D Shakir SAW Coughtrie AL Behr ER Marshall V Camm AJ

• Cite

  BMJ Open. 2017 Oct 16;7(10):e016627.

Evidence for the hERG Liability of Antihistamines, Antipsychotics, and Anti-Infective Agents: A Systematic Literature Review From the ARITMO Project.

• Author

  Shakir S. Hazell L Raschi E De Ponti F Thomas SH Salvo F Ahlberg Helgee E Boyer S Sturkenboom M

  Shakir S Hazell L Raschi E De Ponti F Thomas SH Salvo F Ahlberg Helgee E Boyer S Sturkenboom M

• Cite

  J Clin Pharmacol. 2017 May;57(5):558-572

Use of atomoxetine and suicidal ideation in children and adolescents: Results of an observational cohort study within general practice in England.

• Author

  Davies M Layton D Coughtrie A Shakir SA.

  Davies M Layton D Coughtrie A Shakir SA

• Cite

  Eur Psychiatry. 2017 Jan;39:11-16.

Utilisation and Tolerability of Aliskiren in the Primary Care Setting in England.

• Author

  Layton D Coughtrie AL Shakir SA. Doe C

  Layton D Coughtrie AL Shakir SA Doe C

• Cite

  J Clin Hypertens (Greenwich). 2016 Dec;18(12):1237-1243

Pattern of Onset and Risk Factors for Peripheral Oedema During Vildagliptin Use: Analysis from the Vildagliptin Prescription-Event Monitoring Study in England.

• Author

  Layton D Coughtrie AL Shakir SA. Qayum N

  Layton D Coughtrie AL Shakir SA Qayum N

• Cite

  Drug Safety 2016 Nov;39(11):1093-1104.

Free to view

Safety of Intranasal Quadrivalent Live Attenuated Influenza Vaccine (QLAIV) in Children and Adolescents: A Pilot Prospective Cohort Study in England

• Author

  S. A. Osborne V. Layton McNaughton R. Lynn E. Coughtrie D. and Shakir

  R.McNaughton E.Lynn V.Osborne A.Coughtrie D.Layton Shakir

• Cite

  Drug Safety. April 2016, Volume 39, Issue 4, pp 323–333

Free to view

Vulnerable Patients and Potential Harms: The Contribution of Observational Research.

• Author

  Deborah Layton

  Deborah Layton

• Cite

  Drug Safety. April 2016, Volume 39, Issue 4, pp 277–280.

Utilisation of extended release quetiapine (Seroquel XL™): Results from an observational cohort study in England.

• Author

  Davies M Osborne V Layton D Shakir SA.

  Davies M Osborne V Layton D Shakir SA

• Cite

  Eur Psychiatry. 2016 Mar;33:61-7

Sudden cardiac and sudden unexpected death related to antipsychotics: A meta-analysis of observational studies

• Author

  Shakir S Raschi E Salvo F Sturkenboom M Pariente A Robinson P Arnaud M Thomas S Fourrier-Réglat A Moore N Hazell On Behalf Of Investigators Of The Aritmo Consortium L4; Investigators of the ARITMO Consortium.

  Shakir S Raschi E Salvo F Sturkenboom M Pariente A Robinson P Arnaud M Thomas S Fourrier-Réglat A Moore N Hazell On Behalf Of Investigators Of The Aritmo Consortium L4; Investigators of the ARITMO Consortium.

• Cite

  Clin Pharmacol Ther. 2016 Mar;99(3):306-14

Contribution of UK Prescription-Based Event Monitoring Methods in the Pharmacovigilance of Psychotropic Medications

• Author

  D. Layton

  Layton D

• Cite

  Chapter in "Pharmacovigilance in Psychiatry", 2016, edited by Edoardo Spina and Gianluca Trifirò, published by ADIS

Free to view

The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project.

• Author

  Hazell L Raschi E Salvo F Sturkenboom M Pariente A Poluzzi E Koci A Suling M Antoniazzi S Perina L Moretti U Garbe E De Ponti F.

  Hazell L Raschi E Salvo F Sturkenboom M Pariente A Poluzzi E Koci A Suling M Antoniazzi S Perina L Moretti U Garbe E De Ponti F.

• Cite

  Drug Safety 2016 Jan Volume39(1):59–68

Free to view

Specialist Cohort Event Monitoring Studies: a New Study Method in Risk Management in Pharmacovigilance

• Author

  Shakir SAW Layton D

  Shakir SAW Layton D

• Cite

  Drug Safety February 2015, Volume 38(2): 153–163

Free to view

Specialist Cohort Event Monitoring Studies: a New Study Method for Risk Management in Pharmacovigilance

• Author

  Layton D and Shakir SAW

  Layton D Shakir SAW

• Cite

  Drug Safety February 2015, Volume 38(2): 153–163

Implications of off-label use: An example from the final results of an observational cohort study on Intrinsa® (testosterone patch).

• Author

  Osborne V Layton D Shakir SA

  Osborne V Layton D Shakir SA

• Cite

  Post Reprod Health. 2014 Jun;20(2):48-54

Utilization of fentanyl buccal tablets in England: Exploring off-label use reported in a cohort study.

• Author

  Osborne V Layton D Fogg C Shakir SA. Al-Shukri M

  Osborne V Layton D Fogg C Shakir SA Al-Shukri M

• Cite

  Eur J Pain. 2014 Apr;18(4):506-12.

An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making.

• Author

  Shakir S. McNaughton R Huet G

  Shakir S McNaughton R Huet G

• Cite

  BMJ Open. 2014 Jan 15;4(1)

Prescription-Event Monitoring (PEM): The evolution to the new Modified PEM and its support of risk management.

• Author

  Layton D and Shakir S.

  Layton D Shakir S

• Cite

  Mann's Pharmacovigilance, Third Edition. Ed: E B Andrews and N Moore. John Wiley & Sons Ltd. UK. 2014

Free to view

The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies

• Author

  Hazell L Pladevall M Riera-Guardia N Varas-Lorenzo C Perez-Gutthann S Margulis A Calingaert B Romio S

  Hazell L Pladevall M Riera-Guardia N Varas-Lorenzo C Perez-Gutthann S Margulis A Calingaert B Romio S

• Cite

  BMC Cardiovascular Disorders. 2014, 14:129

Free to view

Quality assessment of observational studies in a drug-safety systematic review, comparision of two tools: the Newcastle-Ottawa Scale and the RTI item bank.

• Author

  Hazell L Margulis AV Pladevall M Riera-Guardia N Varas-Lorenzo C Berkman ND Viswanathan M Perez-Gutthann S

  Hazell L Margulis AV Pladevall M Riera-Guardia N Varas-Lorenzo C Berkman ND Viswanathan M Perez-Gutthann S

• Cite

  Clinical Epidemiology. 2014. Volume 6: 359-368

Free to view

Indicators of drug-seeking aberrant behaviours: The feasibility of use in observational post-marketing cohort studies for risk management.

• Author

  Osborne V Layton D Al-Shukri M and Shakir S.

  Osborne V Layton D Al-Shukri M Shakir S

• Cite

  Drug Safety 2014 Volume 37(8): 639-650

Free to view

Genome wide analysis of drug-induced torsades de pointes: lack of common variants with large effect sizes.

• Author

  Shakir S Behr ER Marshall V Camm AJ Ritchie MD Tanaka T Kääb S Crawford DC Nicoletti P Floratos A Sinner MF Kannankeril PJ Wilde AA Bezzina CR Schulze-Bahr E Zumhagen S Guicheney P Bishopric NH Dalageorgou C Bevan S Jamshidi Y Bastiaenen R Myerburg RJ Schott JJ Steinbeck G Norris K Altman RB Tatonetti NP Jeffery S Kubo M Nakamura Y Shen Y George AL Jr Roden DM.

  Shakir S Behr ER Marshall V Camm AJ Ritchie MD Tanaka T Kääb S Crawford DC Nicoletti P Floratos A Sinner MF Kannankeril PJ Wilde AA Bezzina CR Schulze-Bahr E Zumhagen S Guicheney P Bishopric NH Dalageorgou C Bevan S Jamshidi Y Bastiaenen R Myerburg RJ Schott JJ Steinbeck G Norris K Altman RB Tatonetti NP Jeffery S Kubo M Nakamura Y Shen Y George AL Jr Roden DM.

• Cite

  PLoS One. 2013 Nov 6;8(11):e78511

Neuropsychiatric events with varenicline: a modified prescription-event monitoring study in general practice in England.

• Author

  Layton D Fogg C Shakir SA Buggy Y Cornelius V Kasliwal R

  Layton D Fogg C Shakir SA Buggy Y Cornelius V Kasliwal R

• Cite

  Drug Saf. 2013 Jul;36(7):521-31.

Safety Profile of Modafinil Across a Range of Prescribing Indications, Including Off-Label Use, in a Primary Care Setting in England : Results of a Modified Prescription-Event Monitoring Study

• Author

  Davies M Wilton L and Shakir S

  Davies M Wilton L Shakir S

• Cite

  Drug Saf. 2013 Apr;36(4):237-46

How Do Patients Contribute to Signal Detection? : A Retrospective Analysis of Spontaneous Reporting of Adverse Drug Reactions in the UK’s Yellow Card Scheme

• Author

  Shakir S Hazell L Cornelius V Hannaford P Avery AJ; Yellow Card Study Collaboration

  Shakir S Hazell L Cornelius V Hannaford P Avery AJ; Yellow Card Study Collaboration

• Cite

  Drug Saf. 2013 Mar;36(3):199-206

Reasons for and time to discontinuation of rimonabant therapy: a Modified Prescription-Event Monitoring Study

• Author

  Layton D Buggy Y Willemen M Mantel-Teeuwise Straus S Leufkens H and Egberts T

  Layton D Buggy Y Willemen M Mantel-Teeuwise Straus S Leufkens H and Egberts T

• Cite

  Drug Saf. 2012 Dec 1;35(12):1147-58